Novartis AG and Madrigal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared

SG&A Spending Patterns: Novartis AG vs. Madrigal Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, understanding spending patterns is crucial for strategic planning. Over the past decade, Novartis AG and Madrigal Pharmaceuticals, Inc. have showcased contrasting approaches in their Selling, General, and Administrative (SG&A) expenses. While Novartis AG, a global leader, consistently allocated around $14 billion annually, Madrigal Pharmaceuticals, Inc., a smaller player, saw a dramatic increase in SG&A spending, surging by over 500% from 2014 to 2023. This growth reflects Madrigal's aggressive expansion and market penetration strategies. Notably, in 2023, Madrigal's SG&A expenses peaked at approximately $108 million, highlighting a significant investment in operational capabilities. These trends underscore the diverse strategies employed by pharmaceutical companies to maintain competitiveness and drive innovation. As the industry continues to evolve, monitoring these financial patterns offers valuable insights into corporate priorities and market dynamics.